Patent 7,459,561: Scope, Claims, and Patent Landscape Analysis
Patent 7,459,561, granted to Johnson & Johnson in 2009, covers a method of administering a medicament comprising paclitaxel for treating cancer. The patent emphasizes a sustained-release formulation delivered via a biodegradable polymer matrix, and claims a specific composition, method of preparation, and use.
What Is the Scope of Patent 7,459,561?
The patent's scope centers on methods of delivering paclitaxel through a biodegradable matrix designed for sustained release in cancer therapy. It encapsulates formulations and methods that:
- Use biodegradable polymers such as polylactic acid or polyglycolic acid (or their copolymers).
- Incorporate paclitaxel within these polymers.
- Achieve prolonged therapeutic levels of paclitaxel at the tumor site.
- Employ specific techniques for fabrication, including solvent evaporation or other techniques to embed the drug uniformly.
The patent explicitly excludes non-biodegradable matrices and methods lacking the specific polymers or release characteristics described.
Key Claims Breakdown
The patent contains 15 claims, with the independent claims focusing on:
Claim 1 (Method):
- Administering a biodegradable polymer matrix with embedded paclitaxel.
- Matrix formulated to release the drug in a controlled, sustained manner over a period, such as days to weeks.
- The method involves implanting or injecting this matrix at a tumor site or a surgical cavity post-resection.
Claim 2 (Composition):
- A sustained-release composition comprising paclitaxel within a biodegradable polymer.
- The composition is characterized by specific release kinetics and loading capacities.
Claim 13 (Preparation):
- A process for preparing the formulation, including dissolving polymers and paclitaxel in a solvent, followed by solvent removal to form the matrix.
Limitations:
- The claims specify certain polymer types and molecular weights.
- They define the drug loading percentage (e.g., 5-20% weight/weight).
- The release profile must maintain certain plasma or tissue concentrations over a defined period.
This scope relates closely to biodegradable drug-eluting implants for localized chemotherapy, restricting claims to specific polymer-drug combinations and methods of manufacture.
Patent Landscape and Competition
Patent Family and Related Patents
- The patent belongs to a family targeting controlled-release polymeric drug delivery systems.
- Prior patents include US 6,706,084 (methods of localized chemotherapy) and US 6,361,778 (biodegradable matrices for drug delivery).
- The patent references earlier formulations like TAXOL (paclitaxel injection, approved in 1992), but distinguishes itself through the sustained-release, biodegradable delivery approach.
Competitors and Similar Patents
- Several patents exist for localized chemotherapy formulations, notably in breast and brain cancer treatments.
- For example, Novartis holds patents on NSC collection methods and formulations for paclitaxel delivery.
- The landscape features multiple patents targeting biodegradable polymer matrices but often with different polymers, release kinetics, or application methods.
Patent Expiry and Legal Status
- The patent is enforceable until 2027, with no pending extensions.
- No significant legal challenges or invalidity actions have been publicly reported to date.
- Some jurisdictions have granted alternative formulations, but US patent claims remain specific.
Market and R&D Trends
- Growing interest in implantable drug delivery devices for post-surgical cancer management.
- Ongoing development of bioresorbable polymers with optimized release profiles.
- Regulatory pathways favor localized, controlled-release systems to reduce systemic toxicity.
Technical and Commercial Implications
- The scope’s restriction to specific polymers and manufacturing methods limits competition but provides room for alternative formulations using different biodegradable polymers or drug combinations.
- Therapies using similar polymer matrices but with different drugs or release profiles may avoid infringement.
- Licensing opportunities may exist for companies developing comparable biodegradable implants.
Key Takeaways
- Patent 7,459,561 claims a biodegradable, sustained-release paclitaxel delivery system primarily for local cancer treatment.
- Claims focus on specific polymer compositions and preparation methods, governing scope.
- The patent landscape includes prior and subsequent patents for polymeric drug delivery systems, with ongoing innovation in this segment.
- The patent remains enforceable until 2027, representing a significant asset for Johnson & Johnson.
Frequently Asked Questions
What products are directly covered by Patent 7,459,561?
No commercial products are explicitly tied to this patent; however, it covers proprietary formulations for sustained-release paclitaxel implants or injections used in research and possibly commercial development.
How does this patent differ from conventional paclitaxel formulations?
It differs by its delivery method—implantable biodegradable matrices designed for localized, controlled release over days to weeks—versus systemic administration.
Are there any approved drugs using similar technology?
Existing formulations like paclitaxel-eluting stents and certain biodegradable implants have similar design principles but may not infringe if they do not match the specific polymers or claims of this patent.
Can generic competitors develop similar drug delivery systems?
Yes, if they use different biodegradable polymers, alternate preparation methods, or different release kinetics, they may avoid infringement.
When will this patent expire, and what is its potential impact?
It expires in 2027, after which competitors can develop similar biodegradable, sustained-release paclitaxel systems without licensing restrictions.
References
[1] United States Patent and Trademark Office. (2009). Patent No. 7,459,561. Retrieved from USPTO database.
[2] Johnson & Johnson. (2009). Patent family documentation.
[3] FDA. (1992). Paclitaxel (Taxol) approval documentation.
[4] Novartis. (Various patents). Competitor patent filings related to paclitaxel formulations.
[5] WIPO. Patent landscape reports on biodegradable drug delivery systems.
